Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
Healthcare
$76.99 +1.71%
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
52W Low $9.10High $35.80
Volume 0.00M
Average 0.30M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$50.88M
FY 2025 · Annual
Investing Cash Flow
$36.23M
FY 2025 · Annual
Financing Cash Flow
$69.36M
FY 2025 · Annual
+33.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.71M) | (13.88M) | (31.48M) | (35.48M) | (69.38M) |
| Depreciation & Amortization | 36K | 0 | 9K | 39K | 64K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 1.04M |
| Stock-Based Compensation | 4.21M | 4.02M | 3.28M | 3.1M | 6.26M |
| Change in Working Capital | 720K | 1.68M | (392K) | 1.76M | 11.37M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (294K) | 207K | 271K | 3.02M | 5.54M |
| Other Working Capital | 1.01M | 1.47M | (663K) | (1.26M) | 5.83M |
| Other Non-Cash Items | 61K | 0 | (131K) | (158K) | (237K) |
| Operating Cash Flow | (16.68M) | (8.19M) | (28.71M) | (30.75M) | (50.88M) |
| Capital Expenditures | 0 | 0 | (88K) | (37K) | (116K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (9.97M) | (35.96M) | 0 |
| Sales of Investments | 0 | 0 | 10.1M | 0 | 36.35M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 47K | (35.99M) | 36.23M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 62K | 7.23M | 24.74M | 53M | 76.83M |
| Common Stock Repurchased | 0 | 0 | 0 | (1K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (106K) | 12K | (44K) | (1.14M) | (7.47M) |
| Financing Cash Flow | (44K) | 7.24M | 24.68M | 51.86M | 69.36M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (16.72M) | (944K) | (3.98M) | (14.88M) | 54.71M |
| Free Cash Flow | (16.68M) | (8.19M) | (28.79M) | (30.78M) | (51M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$69.4M
+ D&A$64.0K
+ Stock-Based Comp$6.3M
+ Deferred Tax$1.0M
+ Working Capital$11.4M
- Other Non-Cash-$237.0K
= Operating Cash Flow-$50.9M
- Capex-$116.0K
= Free Cash Flow-$51.0M
Analysis
FY2025 free cash flow is -$51.0M. FCF conversion is 73.5% of net income. Operating cash flow was -$50.9M, with capex of -$116.0K. The largest bridge item is Working Capital at $11.4M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 14D9/A | SC 14D9/A filing | Aug 21, 2026 | |
| SC TO-T/A | SC TO-T/A filing | Aug 19, 2026 | |
| SC 14D9/A | SC 14D9/A filing | Aug 19, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 13, 2026 |
Does FBRX generate free cash flow?
Forte Biosciences, Inc. (FBRX) generated -$51.00M of free cash flow in fiscal 2025.
How much operating cash flow does FBRX produce?
Operating cash flow was -$50.88M, before capital expenditures of $116,000.00.
Continue the stock analysis
Jump to another research area for this company.